On Friday, FDA Granted Accelerated Approval To Sanofi's Tzield (Teplizumab-mzwv) To Delay Decline In Endogenous (Own) Insulin Production In Children Aged 8 To 17 Years Recently Diagnosed With Stage 3 Type 1 Diabetes

Loading news article.

On Friday, FDA Granted Accelerated Approval To Sanofi's Tzield (Teplizumab-mzwv) To Delay Decline In Endogenous (Own) Insulin Production In Children Aged 8 To 17 Years Recently Diagnosed With Stage 3 Type 1 Diabetes | WAPE

On Friday, FDA Granted Accelerated Approval To Sanofi's Tzield (Teplizumab-mzwv) To Delay Decline In Endogenous (Own) Insulin Production In Children Aged 8 To 17 Years Recently Diagnosed With Stage 3 Type 1 Diabetes

Article summary

Related companies

Comments —